Responses
Clinical/translational cancer immunotherapy
Original research
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
